Dimensional Fund Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-412,246
| Closed | -$1.86M | – | 3351 |
|
|
2025
Q2 | $1.86M | Sell |
412,246
-6,308
| -2% | -$28.4K | ﹤0.01% | 2776 |
|
|
2025
Q1 | $1.86M | Sell |
418,554
-44,681
| -10% | -$259K | ﹤0.01% | 2745 |
|
|
2024
Q4 | $3.63M | Sell |
463,235
-14,429
| -3% | -$176K | ﹤0.01% | 2629 |
|
|
2024
Q3 | $6.28M | Sell |
477,664
-6,767
| -1% | -$85.8K | ﹤0.01% | 2455 |
|
|
2024
Q2 | $5.85M | Buy |
484,431
+65,732
| +16% | +$887K | ﹤0.01% | 2445 |
|
|
2024
Q1 | $6.81M | Buy |
418,699
+105,598
| +34% | +$1.42M | ﹤0.01% | 2465 |
|
|
2023
Q4 | $2.14M | Buy |
313,101
+71,512
| +30% | +$414K | ﹤0.01% | 2776 |
|
|
2023
Q3 | $1.32M | Buy |
241,589
+112,091
| +87% | +$653K | ﹤0.01% | 2862 |
|
|
2023
Q2 | $879K | Buy |
129,498
+20,066
| +18% | +$150K | ﹤0.01% | 2951 |
|
|
2023
Q1 | $548K | Sell |
109,432
-11,704
| -10% | -$47.8K | ﹤0.01% | 3015 |
|
|
2022
Q4 | $592 | Sell |
121,136
-11,475
| -9% | -$83.4K | ﹤0.01% | 3007 |
|
|
2022
Q3 | $1.91M | Sell |
132,611
-87,356
| -40% | -$1.45M | ﹤0.01% | 2721 |
|
|
2022
Q2 | $3.33M | Buy |
219,967
+36,599
| +20% | +$427K | ﹤0.01% | 2583 |
|
|
2022
Q1 | $2.18M | Sell |
183,368
-8,434
| -4% | -$86.6K | ﹤0.01% | 2805 |
|
|
2021
Q4 | $3.11M | Buy |
191,802
+66,280
| +53% | +$1.42M | ﹤0.01% | 2718 |
|
|
2021
Q3 | $3.58M | Buy |
+125,522
| New | +$3.96M | ﹤0.01% | 2675 |
|
Other funds holding YMAB
Dimensional Fund Advisors's YMAB Position: Q3 2025 in Review
Dimensional Fund Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 412,246 shares — an estimated $1.86M sold.
Dimensional Fund Advisors first reported a position in YMAB in Q3 2021 and held it in 16 quarters. The position peaked at $6.81M in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Dimensional Fund Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Dimensional Fund Advisors sold 412,246 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.86M.
- Dimensional Fund Advisors first reported a position in Y-mAbs Therapeutics in Q3 2021 and held it in 16 quarters.
- Dimensional Fund Advisors's Y-mAbs Therapeutics position peaked at $6.81M in Q1 2024.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Dimensional Fund Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.